FDA slams Perrigo for metal-tainted tablets

With Johnson & Johnson's consumer healthcare unit partially sidelined by a big recall, you'd think it would be a prime opportunity for Perrigo, which churns out generic versions of many of the recalled meds. Indeed, Mad Money's Jim Cramer touted the company for just that reason: "If Perrigo can scoop up even a large fraction of JNJ's lost sales," Cramer said, "then that would be a big break for this company." But Perrigo is facing manufacturing problems of its own, according to a new warning letter from FDA.

The company recently shipped ibuprofen tablets contaminated with metal shavings, the FDA said in its warning letter, after failing to thoroughly investigate why some tablets came out the wrong size. The company also failed to inspect its packaging equipment between batches. The contaminated tablets have since been pulled from the market, the letter states.

The agency demanded that Perrigo fix its manufacturing problems, or FDA could seize its products, impose an injunction, ban its exports and stop considering its application for new-product approvals.

This isn't the first time Perrigo's manufacturing has run afoul of FDA rules. Four years ago, the company recalled acetaminophen pills that contained pieces of wire as long as 8 millimeters, Bloomberg reports. "Your firm has had an ongoing program since 2005 to address mix-ups," FDA district director Joann M. Givens wrote in the latest warning letter. "However, your firm continues to receive complaints regarding this issue, and despite past assurances that previous enhancements would control the problem, deviations continue."

- check out the FDA warning letter
- read the Bloomberg story
- get the news from WWMT-TV
- see the Mad Money piece

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.